Increased Incidence of Well-Differentiated Thyroid Cancer Associated with Hashimoto Thyroiditis and the Role of the PI3k/Akt Pathway

Journal of the American College of Surgeons

Volumn 204, Issue 5, 2007, Pages 764-773

  Larson, Shawn D ^a   Jackson, Lindsey N ^a   Riall, Taylor S ^a   Uchida, Tatsuo ^b   Thomas, Robert P ^a   Qiu, Suimin ^a   Evers, B Mark ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CARCINOGENESIS; CHILD; DATA BASE; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HASHIMOTO DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID CANCER; THYROID SURGERY; TISSUE SECTION; UNITED STATES;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADOLESCENT; ADULT; AGED; BIOPSY; FEMALE; HASHIMOTO DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; SEER PROGRAM; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 34247534062     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2006.12.037     Document Type: Article

References (37)

1. SEER Program. SEER program public-use data (1973-2003). Available at: http://seer.cancer.gov. Accessed: February 14, 2007.
2. Hundahl S.A., Fleming I.D., Fremgen A.M., and Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. [see comments]. Cancer 83 (1998) 2638-2648
3. Farrow B., and Evers B.M. Inflammation and the development of pancreatic cancer. Surg Oncol 10 (2002) 153-169
4. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
5. Kinzler K.W., and Vogelstein B. Landscaping the cancer terrain. Science 280 (1998) 1036-1037
6. Cipolla C., Sandonato L., Graceffa G., et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg 71 (2005) 874-878
7. Dailey M.E., Lindsay S., and Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70 (1955) 291-297
8. Crile Jr. G. Struma lymphomatosa and carcinoma of the thyroid. Surg Gynecol Obstet 147 (1978) 350-352
9. Holm L.E., Blomgren H., and Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312 (1985) 601-604
10. Ott R.A., McCall A.R., McHenry C., et al. The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am Surg 53 (1987) 442-445
11. Shands W.C. Carcinoma of the thyroid in association with struma lymphomatosa (Hashimoto's disease). Ann Surg 151 (1960) 675-682
12. Singh B., Shaha A.R., Trivedi H., et al. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 126 (1999) 1070-1076 discussion 1076-1077
13. Jackson L., and Evers B.M. Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 130 (2006) 39-65
14. Blume-Jensen P., and Hunter T. Oncogenic kinase signalling. Nature 411 (2001) 355-365
15. Wang Q., Li N., Wang X., et al. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line. Clin Cancer Res 8 (2002) 1940-1947
16. Procko E., and McColl S.R. Leukocytes on the move with phosphoinositide 3-kinase and its downstream effectors. Bioessays 27 (2005) 153-163
17. Miyakawa M., Tsushima T., Murakami H., et al. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 50 (2003) 77-83
18. Ringel M.D., Hayre N., Saito J., et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61 (2001) 6105-6111
19. Rychahou P.G., Jackson L.N., Silva S.R., et al. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243 (2006) 833-844
20. Vasko V., Saji M., Hardy E., et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41 (2004) 161-170
21. Stambolic V., and Woodgett J.R. Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol 16 (2006) 461-466
22. Myers M.P., Pass I., Batty I.H., et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 95 (1998) 13513-13518
23. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 (2004) 2954-2963
24. Shinohara M., Chung Y.J., Saji M., and Ringel M.D. Akt in thyroid tumorigenesis and progression. Endocrinology (2006) August 31, [Epub].
25. Frisk T., Foukakis T., Dwight T., et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer 35 (2002) 74-80
26. Halachmi N., Halachmi S., Evron E., et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23 (1998) 239-243
27. SAS/STAT 9.1 user's guide (2004), SAS Institute Inc, Cary, NC
28. Meier D.W., Woolner L.B., Beahrs O.H., and McConahey C.W. Parenchymal findings in thyroidal carcinoma: pathologic study of 256 cases. J Clin Endocrinol Metab 19 (1959) 162-171
29. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 (2006) 2164-2167
30. Arif S., Blanes A., and Diaz-Cano S.J. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41 (2002) 357-362
31. Loh K.C., Greenspan F.S., Dong F., et al. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 84 (1999) 458-463
32. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 (2003) 257-262
33. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
34. Yoeli-Lerner M., Yiu G.K., Rabinovitz I., et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20 (2005) 539-550
35. Arboleda M.J., Lyons J.F., Kabbinavar F.F., et al. Overexpression of AKT2/protein kinase leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63 (2003) 196-206
36. Cantley L.C., and Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96 (1999) 4240-4245
37. Yeh J.J., Marsh D.J., Zedenius J., et al. Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. Genes Chromosomes Cancer 26 (1999) 322-328